Jan 31, 2026

Clots, Capital, and Deal Activity in the Thrombectomy Devices Market

Clots, Capital, and Deal Activity in the Thrombectomy Devices Market

Recent news in the thrombectomy devices market, including Inquis Medical’s $75M Series C round and Boston Scientific’s planned acquisition of Penumbra for $14.5B

Thrombectomy is the focus this week, with two major announcements that could meaningfully move this space forward. One came from Inquis Medical, which announced a $75 million Series C round backed by an undisclosed strategic investor. The other came from Boston Scientific, which announced plans to acquire Penumbra for $14.5 billion, marking the largest acquisition in Boston Scientific’s history.

Together, these headlines point to a market where mechanical clot removal is gaining momentum across multiple indications. The thrombectomy devices market remains underpenetrated in several of its largest patient populations, which is helping drive both investment and M&A activity.

What Thrombectomy Means in Practice

Thrombectomy refers to the surgical removal of a thrombus, or blood clot. The procedure is a minimally invasive surgery that uses a catheter-based device to mechanically fragment, retrieve, or aspirate clot material to restore blood flow.

The procedure is often used when rapid reperfusion is critical, including:

  • Acute ischemic stroke
  • Venous thromboembolism, such as deep vein thrombosis (DVT) and pulmonary embolism (PE)
  • Peripheral arterial occlusions

In select cases, thrombectomy is also performed in coronary arteries to clear occluded vessels.

Inside the Market Opportunity

Thrombectomy is relevant across several thrombus-related conditions:

  • DVT is the most common, and while many DVT cases are managed medically, procedure volumes remain substantial. DVT represents roughly half of all peripheral thrombectomies performed, of which an estimated 100,000 thrombectomies were performed in the U.S. in 2025, according to internal estimates. 
  • Ischemic stroke is the high-growth segment. U.S. ischemic stroke thrombectomy procedure volumes are expected to grow at a CAGR of 10.0% from 2025 to 2030. By volume, an estimated 50,300 ischemic stroke thrombectomy procedures were performed in the U.S. in 2025.
  • PE, while less common overall, is showing steep growth potential. Penumbra estimates the annual U.S. opportunity at approximately 160,000 patients. In the U.S., there are an estimated 900,000 symptomatic PE cases annually, with 15%–25% categorized as intermediate- to high-risk patients who may advance beyond anticoagulation and thrombolytic therapy. Penumbra estimates the addressable share may be closer to ~44% of PE cases in the U.S.
  • Peripheral arterial occlusion is less frequent than PE, with thrombectomy procedure volumes estimated in the low thousands annually in the U.S.

Inquis Medical’s Series C and the Strategic Investor Question

Inquis Medical is a privately held, commercial-stage company focused on PE intervention. Its flagship product, the AVENTUS™ Thrombectomy System, is intended for PE treatment and incorporates two differentiating features:

  • TrueClot™ Sensing technology, which uses Electrical Impedance Spectroscopy at the catheter tip to distinguish between clot, blood, and vessel wall.
  • Integrated filtration, which separates clot material and allows filtered blood to be reinfused into the patient.

The Series C financing is intended to help Inquis scale commercial operations following FDA 510(k) clearance for AVENTUS in June 2025.

The size of the round and the presence of a single unnamed strategic investor make the deal unusual. Boston Scientific initially seemed like a plausible candidate, given its acquisition pace, but the Penumbra announcement later in the week complicates that assumption.

Other possible strategics discussed include Medtronic, which competes across thrombectomy segments and has a history of large strategic investments, and Terumo, which has an established vascular strategy and active VC presence.

Stryker appears less likely, given its acquisition of Inari Medical for $4.9 billion last year and limited evidence of strategic minority investments.

Boston Scientific to Acquire Penumbra for $14.5 Billion

Boston Scientific’s announced acquisition of Penumbra follows its earlier announcement that it is acquiring Valencia Technologies. The Penumbra deal brings Boston Scientific’s acquisition count to six year-to-date and 10 over the past two years.

Boston Scientific has built an estimated $200 million thrombectomy business around AngioJet™ and EKOS™, though some analysts suggest these assets may need to be divested for the transaction to proceed.

Penumbra reported early FY25 results showing annual revenue growth of roughly 17% compared to FY24. In 2024, Penumbra’s thrombectomy business grew approximately 20% compared to 2023.

Penumbra is widely considered a market leader in thrombectomy, and Boston Scientific will now own that position.

Closing Thoughts

This was a major week for thrombectomy, with strategic investment flowing into Inquis Medical and Boston Scientific announcing its largest acquisition ever with Penumbra. Across stroke, PE, and other clot-related indications, thrombectomy remains a large, underpenetrated opportunity, and these two deals reflect growing confidence in the long-term trajectory of the thrombectomy devices market.